Restasis: profile and news

Allergan won't be alone shedding tears May 14, 2006
That's due in large part to promotional efforts, such as Allergan's support for its Restasis prescription eye drops for dry eye. ... - OCRegister,

Dry eye syndrome can be eased May 16, 2006
...warm compresses and lid scrubs. Then there's Restasis, a new drug, the first prescription out for dry eye. We reserve this for more ... - Indianapolis Star,

Inspire Reports First Quarter 2006 Financial Results; Co-Promotion ... May 9, 2006
2006 included $1.3 million from net sales of Elestat(R) (epinastine HCl ophthalmic solution) 0.05% and $2.9 million from net sales of Restasis(R) (cyclosporine ... - Business Wire (press release),

Inspire shares slip on wider 1Q loss May 9, 2006
Street expectations with $5.5 million in first quarter revenue, most of which came from the company's co-promotion of eye drop products Elestat and Restasis. ... - Triangle Business Journal,

Inspire Pharmaceuticals’ Revenues Jump, But So Do Expenses May 9, 2006
...company said Tuesday. Sales of eye treatment drugs Elestat and Restasis climbed to $1.3 million and $2.9 million. The company also ... - Local Tech Wire,

Itchy, Burning Eyes Can be Sign of Dry Eye Syndrome May 1, 2006
...involves placing filter-paper strips under the lower eyelids to measure the rate of tear production, ophthalmologists may also prescribe Restasis, the only ... - Newswise (press release)

Inspire Announces Date for Conference Call and Webcast to Discuss ... Apr 25, 2006
Inspire's US specialty sales force promotes Elestat(R) (epinastine HCl ophthalmic solution) 0.05% and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05 ... - Genetic Engineering News,

Allergan Reports First Quarter Operating Results; Pharmaceutical ... May 3, 2006
Alphagan P, Alphagan and Combigan $71.0 $66.7 $4.3 $5.2 $(0.9) Lumigan 72.9 62.0 10.9 12.1 (1.2) Other Glaucoma 4.4 4.6 (0.2) (0.1) (0.1) Restasis 66.1 37.3 ... - Genetic Engineering News,

Inspire reports wider loss May 9, 2006
...ago. Higher sales of the dry-eye treatment Elestat and the allergy treatment Restasis accounted for part of the revenue increase. ... - News & Observer,

NPS Pharmaceuticals Reports First Quarter 2006 Operating Results May 2, 2006
...to market research, educational and commercial activities associated with PREOS and our promotional activities associated with Kineret(R) and Restasis(R), a ... - MSN Money